BRIEF-Aeterna zentaris to file a NDA for zoptrex in first half of 2017
June 6 (Reuters) - Aeterna Zentaris Inc
* Aeterna Zentaris reconfirms commitment to LHRH-receptor targeting zoptrex during 2016 ASCO annual meeting
* Phase III trial for endometrial cancer expected to be completed in Q3 2016
* To file a new drug application for zoptrex in first half of 2017 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)
© Thomson Reuters 2017 All rights reserved.